Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.71 |
| ▸ | STS | P08842 | 18/20 | 0.68 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA9 | Q16790 | 2/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA6 | P23280 | 1/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.55 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12379776 | 1.00 | HSD17B1 (0.71) | HSD17B1STSCA1CA2CA9 | |
| SCHEMBL5168726 | 0.85 | STS (0.71) | STSCA1CA2CA9ESR1 | |
| SCHEMBL12379779 | 0.84 | STS (0.69) | HSD17B1STSCA2CA9 | |
| SCHEMBL5664255 | 0.84 | STS (0.69) | HSD17B1STSCA2CA9 | |
| SCHEMBL12379708 | 0.84 | HSD17B1 (0.66) | HSD17B1STSCA1CA2CA9 | |
| SCHEMBL12379704 | 0.83 | HSD17B1 (1.00) | HSD17B1STSESR1ESR2CYP2C9 | |
| SCHEMBL1977371 | 0.83 | HSD17B1 (1.00) | HSD17B1STSESR1ESR2CYP2C9 | |
| SCHEMBL5658818 | 0.83 | HSD17B1 (1.00) | HSD17B1STSESR1ESR2CYP2C9 | |
| SCHEMBL12379702 | 0.83 | HSD17B1 (0.67) | HSD17B1STSCA1CA2CA9 | |
| Emate SCHEMBL6370815 | 0.81 | STS (1.00) | HSD17B1STSCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074060-A1 | Compound | STERIX LIMITED (GB) | 2006-04-06 | — | — | US | disclosed |
| EP-1631579-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004085457-A2 | 17BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074060-A1 | Compound | HAT1, CBR3, ADH5 | HSD17B1 687/4885STS 323/4885CA1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.